Abbott Laboratories Q1 FY26: where the revenue came from and where it went
The whole income statement of Abbott Laboratories for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- Apr 29, 2026
Revenue$11.16B
+8% year over year
Gross profit$6.27B
56% margin
Operating profit$1.35B
12% margin
Net profit$1.08B
10% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 11.16 | 100% | +8% |
| Medical devices | 5.54 | 50% | +13% |
| Diagnostic products | 2.18 | 19% | +6% |
| Nutritional products | 2.02 | 18% | −6% |
| Established pharmaceutical | 1.43 | 13% | +13% |
| Cost of revenue | −4.89 | 44% | |
| Gross profit | 6.27 | 56% margin | −1pp |
| R&D | −0.77 | 7% | +0pp |
| SG&A | −3.74 | 33% | +4pp |
| Other | −0.42 | 4% | +0pp |
| Operating profit | 1.35 | 12% margin | −4pp |
| Other income, net | 0.10 | ||
| Tax | −0.37 | ||
| Net profit | 1.08 | 10% margin | −3pp |
378 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest